신경병증성 통증 시장 규모, 점유율, 성장 분석 : 유형별, 제품 유형별, 시술별, 기술별, 모달리티별, 구입 방법별, 지역별 - 업계 예측(2026-2033년)

Neuropathic Pain Market size was valued at USD 2.83 Billion in 2024 and is poised to grow from USD 2.98 Billion in 2025 to USD 4.51 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

The rising prevalence of chronic conditions, particularly diabetes, alongside an aging population, significantly contributes to the increasing incidence of neuropathic pain. This trend is further fueled by ongoing research and development efforts focused on innovative treatments and pharmaceutical interventions, fostering market expansion. Greater awareness among healthcare professionals and patients regarding effective management options for neuropathic pain highlights this growing sector. The market remains dynamic, with pharmaceutical companies actively launching new medications and therapeutic approaches aimed at addressing the unmet medical needs associated with neuropathic pain, enhancing treatment outcomes and improving patient quality of life. Overall, these factors indicate a promising outlook for the neuropathic pain treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neuropathic Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segments Analysis

Global Neuropathic Pain Market is segmented by Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel and region. Based on Type, the market is segmented into Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy and Proximal Neuropathy. Based on Product Type, the market is segmented into Rechargeable and Non-Rechargeable. Based on Procedure, the market is segmented into Invasive and Non-Invasive. Based on Technology, the market is segmented into Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation. Based on Modality, the market is segmented into Stationary and Portable. Based on Mode of Purchase, the market is segmented into Over-the-Counter Devices and Prescription-Based Devices. Based on Pain Type, the market is segmented into Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain and Coccydynia. Based on Indication, the market is segmented into Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy and Others. Based on Diagnosis, the market is segmented into Imaging, Blood Tests and Physical Examination. Based on Treatment, the market is segmented into Medications and Multimodal Therapy. Based on End User, the market is segmented into Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Third Party Distributor and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neuropathic Pain Market

The rising prevalence of chronic conditions such as diabetes, various cancers, and neurological disorders has significantly contributed to a growing number of neuropathic pain cases worldwide. As populations age, the associated risk factors for neuropathic pain increase, further driving demand in the market. Additionally, continuous advancements in scientific research and pharmaceutical development play a crucial role in creating innovative medications and therapies specifically targeting neuropathic pain, thereby improving treatment options. This combination of increasing chronic illness rates and advancements in medical solutions supports a robust market environment for addressing the complexities of neuropathic pain effectively.

Restraints in the Neuropathic Pain Market

A significant constraint in the neuropathic pain market arises from the challenges in diagnosis and the inherently subjective nature of pain assessment, which complicates the accurate identification and measurement of neuropathic pain. This can result in underreporting or insufficient management of the condition. Additionally, the elevated costs associated with advanced treatment options and medications can limit accessibility, particularly in regions where healthcare budgets are constrained. These factors combined create substantial barriers to effectively addressing and managing neuropathic pain, ultimately affecting both patients' welfare and the overall market growth.

Market Trends of the Neuropathic Pain Market

The neuropathic pain market is witnessing a significant trend towards the development of innovative treatment modalities and pharmaceutical interventions, underscoring the sector's dynamic evolution. This shift is driven by ongoing research and advancements that aim to enhance therapeutic efficacy and patient outcomes. Additionally, the proliferation of telehealth services and virtual health solutions is transforming the landscape of neuropathic pain management. These technologies facilitate more accessible and personalized care, enabling patients to receive timely diagnoses, continuous monitoring, and tailored treatment plans that effectively address their unique needs. This combination of innovation and accessibility is redefining pain management strategies, fostering better quality of life for individuals affected by neuropathic pain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Neuropathic Pain Market Size by Type & CAGR (2026-2033)

• Market Overview
• Spinal Cord Stimulation (SCS) Devices
• External Peripheral Nerve Stimulation
• Transcutaneous Electrical Nerve Stimulation (TENS) Devices
• Focal Neuropathy
• Automatic Neuropathy
• Proximal Neuropathy

Global Neuropathic Pain Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Rechargeable
• Non-Rechargeable

Global Neuropathic Pain Market Size by Procedure & CAGR (2026-2033)

• Market Overview
• Invasive
• Non-Invasive

Global Neuropathic Pain Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

Global Neuropathic Pain Market Size by Modality & CAGR (2026-2033)

• Market Overview
• Stationary
• Portable

Global Neuropathic Pain Market Size by Mode of Purchase & CAGR (2026-2033)

• Market Overview
• Over-the-Counter Devices
• Prescription-Based Devices

Global Neuropathic Pain Market Size by Pain Type & CAGR (2026-2033)

• Market Overview
• Peripheral Neuropathy
• Entrapment Neuropathy
• Phantom Limb Neuropathy
• Trigeminal Neuralgia
• Post Herpetic Neuralgia (PHN)
• Post Traumatic Neuropathy
• Foot Pain
• Coccydynia

Global Neuropathic Pain Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Spinal Stenosis
• Chemotherapy-Induced Peripheral Neuropathy
• Diabetic Neuropathy
• Others

Global Neuropathic Pain Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging
• Blood Tests
• Physical Examination

Global Neuropathic Pain Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medications
• Multimodal Therapy

Global Neuropathic Pain Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Research Organization
• Others

Global Neuropathic Pain Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Tender
• Third Party Distributor
• Others

Global Neuropathic Pain Market Size & CAGR (2026-2033)

• North America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations